Atty's 23518 Pat. App. Not known - US phase of PCT/DE2004/001738

AMENDED NEW PATENT CLAIMS:

1

1

2

3

5

6

- (original) A peptide according to sequence number 1.
- 2. (original) The peptide according to claim 1 characterized in that it is in solid, semiliquid or liquid form.
- 3. (currently amended) The peptide according to claim 1
 er-2 characterized in that it is in the form of an injection
 solution, drop, juice, syrup, spray, suspension, granulate, tablet,
 pellet, transdermal therapeutic system, capsule, plaster,
 suppository, salve, cream, lotion, gel, emulsion or aerosol form.
 - 4. (original) The peptide according to claim 3 characterized in that it contains an auxiliary substance like, for example, a carrier, a filler, a solvent, a diluent, a surface active substance, a coloring agent, a preservative, a bursting agent, a smoothing agent, a lubricant, an aromatizing agent and/or a binder.
- 5. (currently amended) The peptide according to ene of
 claims 1 to 4 claim 1 characterized in that it is modified or
 substituted by at least one component from the group of sugar
 residues, glucoromic acid, sulfate residues, serine, glycine or
 aspartate.

Atty's 23518 Pat. App. Not known - US phase of PCT/DE2004/001738

- 6. (original) A method of making an agent according to
 7 claim 1 characterized in that a solid phase synthesis in a liquid
 8 phase is used.
- 7. (original) The method of making an agent according to claim 1 characterized in that a peptide according to claim 1 is expressed by a nucleic acid coding for this peptide sequence.
- 8. (original) The use of the peptide according to claim
 1 for producing a pharmaceutical.
- 9. A healing or treatment method as well as a method of preventing the illness TSE characterized in that the patient is enriched with a peptide according to claims 1 to 5.